Humacyte PR

Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the virtual Oppenheimer 31st Annual Healthcare Conference March 18, 2021, at 8:40 a.m. EDT. On February 17, 2021, …

Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference Read More »

Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021

DURHAM, N.C., March 05, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the clinical results of five-year outcomes in patients receiving the human acellular vessels (HAV) for arteriovenous (AV) access in hemodialysis have been accepted for oral presentation at the …

Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021 Read More »

Humacyte, a Transformative Biotechnology Platform Company Capable of Manufacturing Universally Implantable Bioengineered Human Tissue at Commercial Scale Going Public via Merger with Alpha Healthcare Acquisition Corp.

Humacyte aims to transform medicine with off-the-shelf, universally implantable, bioengineered human tissue available at commercial scale. Transaction values Humacyte at a pre-money valuation of $800 million with existing Humacyte shareholders rolling over 100% of their equity into equity of the Combined Company. Following transaction closing, Humacyte is expected to have a market capitalization of $1.1 …

Humacyte, a Transformative Biotechnology Platform Company Capable of Manufacturing Universally Implantable Bioengineered Human Tissue at Commercial Scale Going Public via Merger with Alpha Healthcare Acquisition Corp. Read More »

Humacyte CEO Dr. Laura Niklason to Present Virtually at ICR Conference Jan 14

DURHAM, N.C. (January 12, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that President and CEO Laura Niklason, M.D., Ph.D. will present virtually at the ICR Conference on January 14 at 12:15 p.m. EST. Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies, including the Company’s late-stage …

Humacyte CEO Dr. Laura Niklason to Present Virtually at ICR Conference Jan 14 Read More »

Humacyte CEO Dr. Laura Niklason to Present at J.P. Morgan Healthcare Conference January 11

DURHAM, N.C. (January 11, 2021) — Humacyte, Inc., a leading innovator in regenerative medicine and biotechnology, announced that Founder and CEO Laura Niklason, M.D., Ph.D. will present virtually at the 39th annual J.P. Morgan Healthcare Conference on January 11 at 8:05 a.m. EST.  Dr. Niklason will present an overview of Humacyte’s groundbreaking regenerative medicine therapies, …

Humacyte CEO Dr. Laura Niklason to Present at J.P. Morgan Healthcare Conference January 11 Read More »

Laura Niklason to Speak at Milken Institute Future of Health Summit

DURHAM, N.C. (December 8, 2020) — Humacyte President and CEO Laura Niklason, M.D., Ph.D. will speak at the renowned Milken Institute Future of Health Summit on Wednesday, December 9 at 1:30 p.m. EST. In a session entitled Bringing It All Together: Innovations in Technology to Change Treatment and Care, Dr. Niklason joins Arjun Desai (Insightec); …

Laura Niklason to Speak at Milken Institute Future of Health Summit Read More »

Humacyte Appoints Founder Laura Niklason MD, PhD as President and Chief Executive Officer

Jeffrey Lawson MD, PhD Appointed Chief Surgical Offcer and Vice Chairman, to Enhance Product Positioning and Clinical Adoption Durham, N.C. – November 20, 2020. Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Laura Niklason MD, PhD has been appointed President and Chief Executive Officer. Jeffrey Lawson MD, PhD has been appointed the …

Humacyte Appoints Founder Laura Niklason MD, PhD as President and Chief Executive Officer Read More »

New Paper Defines Breakthroughs in Vascular Tissue Engineering

Humacyte Executives Add Game-Changing Findings to 40-Year History of Bioengineered Blood Vessels DURHAM, N.C. (October 9, 2020) — A new manuscript published in the highly cited scientific journal Science (also known as Science Magazine) reveals great strides in the field of regenerative medicine and vascular tissue engineering. “The Evolution and Development of Bioengineered Blood Vessels” …

New Paper Defines Breakthroughs in Vascular Tissue Engineering Read More »

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering

Recognized as a Pioneer in Vascular and Lung Engineering and Biomedical Imaging DURHAM, N.C. (BUSINESS WIRE) March 02, 2020—Humacyte, an innovator in biotechnology and regenerative medicine, announced today that company founder, Laura Niklason, M.D., Ph.D., a world leader in tissue engineering and cellular therapies, has been elected to the prestigious National Academy of Engineering (NAE). …

Humacyte Founder Laura Niklason, M.D., Ph.D. Elected to National Academy of Engineering Read More »

Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium

Honor Recognizes Humacyte’s Progress in Accelerating the Manufacturing Platform and Process for Producing Vascular Conduits for Hemodialysis and Vascular Trauma Durham, N.C. –April 8, 2019. Humacyte, an innovator in biotechnology and regenerative medicine, received the Medical Technology Enterprise Consortium (MTEC) Large Project Prototype of the Year Award, in recognition of the development of its human acellular …

Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium Read More »

Scroll to Top